These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30197357)

  • 1. Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience.
    Onec B; Okutan H; Albayrak M; Can ES; Aslan V; Koluman BU; Kosemehmetoglu OS; Albayrak A
    J Cancer Res Ther; 2018; 14(5):1105-1111. PubMed ID: 30197357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
    Radujkovic A; Dietrich S; Bochtler T; Krämer A; Schöning T; Ho AD; Dreger P; Luft T
    Eur J Haematol; 2014 Aug; 93(2):112-7. PubMed ID: 24628527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
    Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
    Vives S; Martínez-Cuadrón D; Bergua Burgues J; Algarra L; Tormo M; Martínez-Sánchez MP; Serrano J; Herrera P; Ramos F; Salamero O; Lavilla E; López-Lorenzo JL; Gil C; Vidriales B; Falantes JF; Serrano A; Labrador J; Sayas MJ; Foncillas MÁ; Amador Barciela ML; Olave MT; Colorado M; Gascón A; Fernández MÁ; Simiele A; Pérez-Encinas MM; Rodríguez-Veiga R; García O; Martínez-López J; Barragán E; Paiva B; Sanz MÁ; Montesinos P;
    Cancer; 2021 Jun; 127(12):2003-2014. PubMed ID: 33626197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
    Lao Z; Yiu R; Wong GC; Ho A
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):54-61. PubMed ID: 25545192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.
    Baba Y; Hida N; Sambe T; Abe M; Kabasawa N; Sakai H; Yoshimura K; Fukuda T
    Anticancer Res; 2024 May; 44(5):2003-2007. PubMed ID: 38677735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide.
    Tsurumi H; Kanemura N; Hara T; Kasahara S; Yamada T; Sawada M; Oyama M; Moriwaki H
    J Cancer Res Clin Oncol; 2007 Aug; 133(8):547-53. PubMed ID: 17453240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
    Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
    Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azacitidine and its role in the upfront treatment of acute myeloid leukemia.
    Raslan O; Garcia-Horton A
    Expert Opin Pharmacother; 2022 Jun; 23(8):873-884. PubMed ID: 35695017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.
    Craddock CF; Houlton AE; Quek LS; Ferguson P; Gbandi E; Roberts C; Metzner M; Garcia-Martin N; Kennedy A; Hamblin A; Raghavan M; Nagra S; Dudley L; Wheatley K; McMullin MF; Pillai SP; Kelly RJ; Siddique S; Dennis M; Cavenagh JD; Vyas P
    Clin Cancer Res; 2017 Nov; 23(21):6430-6440. PubMed ID: 28765326
    [No Abstract]   [Full Text] [Related]  

  • 12. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
    Schaich M; Illmer T; Aulitzky W; Bodenstein H; Clemens M; Neubauer A; Repp R; Schäkel U; Soucek S; Wandt H; Ehninger G;
    Haematologica; 2002 Aug; 87(8):808-15. PubMed ID: 12161356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
    Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
    Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.
    Tombak A; Uçar MA; Akdeniz A; Tiftik EN; Gören Şahin D; Akay OM; Yıldırım M; Nevruz O; Kis C; Gürkan E; Solmaz ŞM; Özcan MA; Yıldırım R; Berber İ; Erkurt MA; Fıratlı Tuğlular T; Tarkun P; Yavaşoğlu İ; Doğu MH; Sarı İ; Merter M; Özcan M; Yıldızhan E; Kaynar L; Mehtap Ö; Uysal A; Şahin F; Salim O; Sungur MA
    Turk J Haematol; 2016 Dec; 33(4):273-280. PubMed ID: 27095141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
    Garcia-Manero G; Kazmierczak M; Wierzbowska A; Fong CY; Keng MK; Ballinari G; Scarci F; Adès L
    Leuk Res; 2024 May; 140():107480. PubMed ID: 38499457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
    J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.